Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTHA HERNANDEZ ILLAS

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1972517464
CMS profile
733063
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$163.00

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $163.00 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $125.00 1
PFIZER INC. $38.00 3

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTHA HERNANDEZ ILLAS

NPI 1972517464 · CMS profile ID 733063

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARTHA HERNANDEZ ILLAS, NPI 1972517464, CMS profile ID 733063, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1972517464?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $163.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $15.4609/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672777395 CMS
Amgen Inc. $125.0008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662726285 CMS
PFIZER INC. $6.7503/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672054747 CMS
PFIZER INC. $15.7901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672016437 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $163.00 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,780,360.32 3
PY2024 Principal investigator $1,857,594.44 9
PY2023 Principal investigator $2,411,538.38 25
PY2022 Recipient $8,492.00 4
PY2022 Principal investigator $6,968,480.90 32
PY2021 Principal investigator $4,588,067.03 55
PY2020 Recipient $1,800.00 2
PY2020 Principal investigator $1,389,670.25 53
PY2019 Principal investigator $5,017,814.30 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $279.00 12/16/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794087
Principal investigator 1 PFIZER INC. $95,451.00 12/16/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742894691
Recipient Eli Lilly and Company $525.00 12/02/2020 Covered Recipient Physician A SINGLE-ASCENDING AND REPEAT-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3561774 No dispute reported 06/30/2026 728720639
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,566.00 11/24/2020 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 737093113
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,267.72 11/23/2020 Non-covered Recipient Entity
Qps Miami Research Associates
A Phase 1 Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 736738031
Principal investigator 1 Amgen Inc. $298.14 11/19/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 890_FIH/ SAD No dispute reported 06/30/2026 731624213
Principal investigator 1 PFIZER INC. $170.43 11/19/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742921805
Principal investigator 1 PFIZER INC. $2,125.00 11/19/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742921907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 11/19/2020 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE No dispute reported 06/30/2026 737092905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 11/19/2020 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE No dispute reported 06/30/2026 737092907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $552.00 11/19/2020 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE No dispute reported 06/30/2026 737092909
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $331.20 11/19/2020 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAMUSCULAR INJECTION OF NOROVIRUS GI.1/GII.4 BIVALENT VIRUS-LIKE PARTICLE VACCINE No dispute reported 06/30/2026 737092911
Principal investigator 1 Merck Sharp & Dohme Corporation $1,392.50 11/12/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794175
Principal investigator 1 PFIZER INC. $5,489.00 10/29/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742921901
Principal investigator 1 Merck Sharp & Dohme Corporation $835.50 10/19/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794093
Principal investigator 1 Merck Sharp & Dohme Corporation $744.00 10/17/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794089
Principal investigator 1 PFIZER INC. $194,742.00 10/17/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742921811
Principal investigator 1 Merck Sharp & Dohme Corporation $1,951.50 10/16/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794179
Principal investigator 1 Merck Sharp & Dohme Corporation $744.00 10/09/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794091
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $618.76 10/08/2020 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 724476509
Principal investigator 1 Merck Sharp & Dohme Corporation $2,230.00 10/07/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794085
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,854.80 09/22/2020 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 737088681
Principal investigator 1 Merck Sharp & Dohme Corporation $2,279.76 09/21/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740704233
Recipient Eli Lilly and Company $1,275.00 09/18/2020 Covered Recipient Physician SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE-ASCENDING SUBCUTANEOUS DOSES OF LY3493269 IN PATIENTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 728722087
Principal investigator 1 PFIZER INC. $478,739.00 09/18/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742921601
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,914.70 09/17/2020 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 724475453
Principal investigator 1 Merck Sharp & Dohme Corporation $1,671.00 09/08/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-RangingTrial to Evaluate the Safety and Immunogenicity of V590 in Healthy Adults No dispute reported 06/30/2026 740794177
Principal investigator 1 PFIZER INC. $10,500.00 08/29/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742921905
Principal investigator 1 PFIZER INC. $250.00 08/20/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742921809
Principal investigator 1 PFIZER INC. $3,491.82 08/20/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742922107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,900.83 08/06/2020 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 724473175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,596.94 07/23/2020 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 724471609
Principal investigator 1 Amgen Inc. $69.60 06/25/2020 Non-covered Recipient Entity
QPS MRA, LLC
AMG 890_FIH/ SAD No dispute reported 06/30/2026 731624219
Principal investigator 1 PFIZER INC. $11,100.00 06/16/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742954855
Principal investigator 1 PFIZER INC. $4,229.61 06/04/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742954939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,712.94 06/04/2020 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 724466767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,713.60 06/02/2020 Non-covered Recipient Entity
MIAMI RESEARCH ASSOCIATES LLC
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 737082301
Principal investigator 1 Amgen Inc. $70,114.00 05/21/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 890_FIH/ SAD No dispute reported 06/30/2026 731624209
Principal investigator 1 PFIZER INC. $3,500.00 05/16/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE ESCALATING ORAL DOSES OF PF07081532 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742954843
Principal investigator 1 PFIZER INC. $15,418.22 04/29/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742954931
Principal investigator 1 PFIZER INC. $21,715.86 04/16/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742954927
Principal investigator 1 Merck Sharp & Dohme Corporation $544.60 03/25/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
A Trial to Assess the Effects of Multiple, Once Weekly Oral Doses of MK-8507 on the Single-Dose Pharmacokinetics of a Combination Oral Contraceptive Levonorgestrel and Ethinyl Estradiol in Healthy Adult Female Participants No dispute reported 06/30/2026 740755151
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,499.00 03/12/2020 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 724457865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,728.25 02/20/2020 Non-covered Recipient Entity
QPS MRA LLC
A RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF REGN5069 IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE No dispute reported 06/30/2026 724455521
Principal investigator 1 PFIZER INC. $21,561.96 02/13/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742973263
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13,356.00 02/03/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 744482311
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $111,294.00 02/01/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 744482307
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $525.00 02/01/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE I STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RC-P IN HEALTHY ADULT SUBJECTS No dispute reported 06/30/2026 744482309
Principal investigator 1 Amgen Inc. $568.75 01/31/2020 Non-covered Recipient Entity
QPS MIAMI RESEARCH ASSOCIATES
AMG 598 - Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 731623571
Principal investigator 1 Amgen Inc. $8,100.00 01/31/2020 Non-covered Recipient Entity
QPS MRA LLC
AMG 598 - Ph 1 Safety; Tolerability; PK and PD of MAD No dispute reported 06/30/2026 731623575
Principal investigator 1 Amgen Inc. $12,748.00 01/31/2020 Non-covered Recipient Entity
QPS MRA LLC
AMG 890_FIH/ SAD No dispute reported 06/30/2026 731624215
Principal investigator 1 PFIZER INC. $110,380.80 01/30/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING ORAL DOSES OF PF06882961 IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 742973403
Principal investigator 1 AstraZeneca Pharmaceuticals LP $102,907.18 01/24/2020 Non-covered Recipient Entity
Qps Mra Llc
A Phase 1 Randomized, Blinded, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of MEDI6570 in Subjects with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 736744923
Principal investigator 1 PFIZER INC. $298.28 01/21/2020 Non-covered Recipient Entity
QPS MRA LLC
A PHASE 1 RANDOMIZED MULTICENTER DOUBLEBLIND SPONSOR OPEN PLACEBOCONTROLLED SINGLE AND MULTIPLE DOSEESCALATION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF PF06835375 IN SUBJECTS WITH SEROPOSITIVE SYSTEMIC LUPUS ERYTHEMATOSUS OR RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 742960827
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,494.00 01/08/2020 Non-covered Recipient Entity
Mra Clinical Research, Llc
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes No dispute reported 06/30/2026 736760995